Eton Pharmaceuticals
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | 21.8m | 21.3m | 31.6m | 36.5m | 47.4m |
% growth | (95 %) | (96 %) | 55879 % | (3 %) | 49 % | 15 % | 30 % |
EBITDA | (18.2m) | (26.5m) | (1.0m) | (6.5m) | (<1m) | (2.3m) | 7.1m |
% EBITDA margin | (1893 %) | (67846 %) | (5 %) | (31 %) | (1 %) | (6 %) | 15 % |
Profit | (18.3m) | (28.0m) | (2.0m) | (9.0m) | (<1m) | (3.8m) | 5.6m |
% profit margin | (1910 %) | (71718 %) | (9 %) | (42 %) | (3 %) | (10 %) | 12 % |
EV / revenue | 133.7x | 5048.7x | 4.8x | 3.4x | 3.5x | 3.3x | 2.5x |
EV / EBITDA | -7.1x | -7.4x | -102.2x | -11.0x | -386.3x | -51.6x | 16.7x |
R&D budget | 11.6m | 14.1m | 6.2m | 4.0m | 3.3m | - | - |
R&D % of revenue | 1205 % | 36164 % | 29 % | 19 % | 10 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $20.0m | Series A | |
N/A | $22.0m Valuation: $102m | IPO | |
N/A | $7.5m | Post IPO Equity | |
* | N/A | Post IPO Equity | |
* | $10.6m | Post IPO Equity | |
Total Funding | AUD30.9m |
Recent News about Eton Pharmaceuticals
EditEton Pharmaceuticals is a specialty pharmaceutical company dedicated to advancing healthcare by developing and commercializing innovative medicines that are both affordable and accessible to all patients. The company focuses on creating proprietary formulations of approved molecules, aiming to improve existing treatments by making them safer, more effective, or less expensive. Eton Pharmaceuticals serves a diverse range of clients, including healthcare providers and patients, primarily within the pharmaceutical and healthcare markets. The business model revolves around continuous product development and portfolio expansion, ensuring a steady pipeline of new and improved medications. Revenue is generated through the commercialization of these proprietary formulations, which are designed to meet unmet medical needs and offer significant improvements over existing products.
Keywords: specialty pharmaceuticals, innovative medicines, proprietary formulations, healthcare, affordable treatments, patient care, product development, portfolio expansion, safer medications, effective treatments.